'Why I paid for my sons to have the HPV jab'
S1 boys are being offered the human papillomavirus vaccine, but GP Carolyn Calder wants the programme extended.
OBJECTIVE: To evaluate the knowledge and acceptability of the human papillomavirus (HPV) vaccine among health professionals from western Amazonia. METHODS: A cross-sectional study was conducted in the Sistema Assistencial è Saúde da Mulher e da Criança (Health Care System for Women and Children; SASMC) in Acre, Brazil, in 2017. The participants comprised 196 health professionals. The data collection instrument contained 31 questions about HPV, its clinical repercussions for women, and the HPV vaccine. Quantitative variables were presented as medians and 95% confidence intervals (CIs), and p
Conditions: HPV Infection; HPV-Related Cervical Carcinoma Interventions: Biological: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha); Biological: Placebo Sponsors: National Vaccine and Serum Institute, China; Chengdu Institute of Biological Products Co.,Ltd.; Simoon Record Pharma Information Consulting Co., Ltd; Guangxi Center for Disease Control and Prevention; Beijing Kantorico Statistical Technology Co., Ltd. Recruiting
Conclusions Public health educational programs that are focused and tailored on parents consenting to HPV vaccination for boys at a young age can be useful in improving HPV vaccination rates among boys. There is also a pressing need to educate boys about the benefits of HPV vaccination in males and about HPV disease susceptibility to facilitate adoption of the HPV vaccine by young adults in the future.
A federal advisory panel says people aged 27 to 45 may benefit from the human papillomavirus vaccine, but some worry that the advice doesn't provide clear guidance about who are candidates for the vaccine.Kaiser Health News
The objective of this quality improvement project was to increase human papillomavirus (HPV) vaccine initiation rates among males aged 11 to 21 years old. A multipronged strategy was implemented at a pediatric practice, including an electronic medical record prompt, educational presentation, and monthly e-mail updates to providers. Deidentified HPV vaccine initiation rate data were collected, and a paired 2-sample t test evaluated differences in prepost vaccine initiation rates. HPV vaccine initiation rates increased by 6.5% during the project period.
Publication date: December 2019Source: Current Opinion in Virology, Volume 39Author(s): Silvia de Sanjose, Maria Brotons, D Scott LaMontagne, Laia BruniSince 2006, 115 countries and territories have introduced human papillomavirus (HPV) vaccination programs.Several efforts have been undertaken to evaluate the impact of HPV vaccines. Many countries, mainly high-income and with high screening coverage, are already reporting a visible impact of the HPV vaccine on HPV-related diseases. Others, largely low-income and middle-income countries, are introducing HPV vaccine to control HPV diseases that will undoubtedly generate a si...
ConclusionOverall, these data support the concomitant administration of HPV4, Tdap and MenACWY-CRM in adolescents.FundingNovartis Vaccines and Diagnostics Inc., now part of the GSK group of companies.Trial RegistrationClinicalTrials.gov identifier, NCT01424644.
Despite the availability of different therapeutic modalities, treatment of recalcitrant common warts is still challenging. Cervarix, a recombinant bivalent human papillomavirus (HPV) vaccine, has shown promising efficacy in the treatment of warts.
CONCLUSION: Due to the low levels of knowledge about HPVinfection and its methods of prevention, efforts should be increased to enhance the knowledge of the general populationabout HPV infection and vaccination in order to prevent its incidence and complications. PMID: 31350949 [PubMed - in process]